Nexalin Technology Announces Publication of Groundbreaking Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal; Validates the Ability of Nexalin’s Neurostimulation Device to Penetrate Deep Brain Structures
16 Outubro 2023 - 9:30AM
Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL;
NXLIW) today announced the publication of a research article
titled, “Evidence of a large current of transcranial alternating
current stimulation directly to deep brain regions,” in Nature’s
Molecular Psychiatry, a leading peer-reviewed journal. The
study publication is available online and can be accessed at:
https://www.nature.com/articles/s41380-023-02150-8.
The study revealed for the first time, that
Nexalin’s non-invasive, deep frequency stimulation medical device
can directly stimulate the deep intracranial nuclei, areas of the
brain frequently associated with trauma and mental health disease.
The study also demonstrated that Nexalin’s non-invasive Deep
Intracranial Frequency Stimulation (DIFS™) has the potential to
treat neuropsychiatric disorders associated with the hippocampus,
insula, amygdala, and other deep nuclei. This achievement not only
moves non-invasive neural stimulation technology from qualitative
treatment to quantitative treatment, but also lays a new
theoretical foundation for future neural stimulation protocols for
the treatment of brain diseases.
Mark White, CEO of Nexalin Technology, stated,
“It is an honor to see this deep-brain study published in a leading
peer-reviewed journal, which reinforces the growing body of
clinical evidence supporting the potential of our non-invasive,
frequency-based, deep-brain stimulation devices in helping address
the global mental health epidemic. The future of neuro-stimulation
relies on depth of penetration in a safe and effective manner.
Historically, all neurostimulators have limited penetration because
of safety and side effects which limits efficacy. We believe
Nexalin’s new advanced proprietary waveform can eliminate issues
with risk and safety while increasing efficacy. The research
results have significant scientific value, ushering in a new era of
non-invasive neural stimulation, which we believe demonstrates
Nexalin is becoming a world leader in this field.”
David Owens, M.D., Chief Medical Officer of
Nexalin Technology, further noted, “To our knowledge, this is the
first study, ever, to demonstrate the effective penetration of
electrical currents through the skull to deeper regions of the
brain. Our study provides direct evidence that specific
deep-frequency stimulation procedures are capable of delivering
electrical currents to deep brain tissues, opening a pathway for
modulating and treating neuropsychiatric disorders associated with
the hippocampus, insula, and amygdala. To date, studies of
competing technologies have only demonstrated penetration of less
than 1 inch, at a maximum tolerated current of 1-2 milliamp
(mA). In contrast, we achieved deep penetration at up to 15
mA, without pain or other side effects. In our opinion, the
findings of this trial represent a major validation of our prior
research demonstrating clinical efficacy. This research also
highlights the broad potential of our neurostimulation devices to
treat neuropsychiatric disorders associated with deep brain
structures, such as depression, anxiety and insomnia. We look
forward to bringing new, effective, safe, non-invasive, and
affordable therapies to patients worldwide affected with mental and
neurological diseases.”
About Nexalin Technology, Inc.
Nexalin designs and develops innovative
neurostimulation products to uniquely and effectively help combat
the ongoing global mental health epidemic. All Nexalin’s products
are non-invasive and undetectable to the human body and provide
relief to those afflicted with mental health issues without adverse
side effects. Nexalin utilizes bioelectronic medical technology to
treat mental health issues without the need for drugs or
psychotherapy. Nexalin believes the 15 milliamp medical device can
penetrate structures deep in the mid-brain that are associated with
mental health disorders. Nexalin believes the deeper penetrating
waveform will generate enhanced patient response without any
adverse side effects. The Nexalin tACS device was recently approved
in China by the National Medical Products Administration (NMPA) for
the treatment of insomnia and depression. In May 2023, Nexalin
formalized a joint venture with Wider Come Limited, a company
formed under the laws of the People’s Republic of China. The
joint venture has been established to engage in the clinical
development, marketing, sale and distribution of the Nexalin device
in the Asia Pacific region. This new entity will conduct clinical
research and implement a business distribution plan for the Nexalin
device in the Asia Pacific region. Additional information about the
Company is available at: https://nexalin.com/.
FORWARD-LOOKING STATEMENTS
This press release contains statements that
constitute “forward-looking statements,” including with respect to
the Company’s initial public offering. Forward-looking statements
are subject to numerous conditions, many of which are beyond the
control of the Company, including those set forth in the Risk
Factors section of the Company’s registration statement and
prospectus for the offering filed with the SEC. Copies are
available on the SEC's website, www.sec.gov. The Company
undertakes no obligation to update these statements for revisions
or changes after the date of this release, except as required by
law.
Contact:Crescendo Communications, LLCTel: (212)
671-1020Email: NXL@crescendo-ir.com
Nexalin Technologies (NASDAQ:NXLIW)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Nexalin Technologies (NASDAQ:NXLIW)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024